A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Trial details
- Registry ID
- NCT06072781
- Drugs studied
- Anastrozole, Defactinib, Letrozole, Paclitaxel and 2 more
TrialRedline tracks 9 clinical trials sponsored by Verastem, Inc.: 1 Phase 3, 7 Phase 2, 1 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerNCT06072781 | Anastrozole, Defactinib, Letrozole, Paclitaxel and 2 more | Recruiting | 2028-10-15Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsNCT07020221 | Carboplatin + Pemetrexed + Pembrolizumab, Cetuximab, Defactinib, Gemcitabine + Nab-paclitaxel and 4 more | Recruiting | 2028-12Estimated |
Names as written in the registry records.
NCT07644559 · Verastem, Inc.
Before: 180 participants (planned). After: 185 participants (planned).
NCT07659782 · Verastem, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT07659795 · Verastem, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT06682572 · Verastem, Inc.
Before: Estimated. After: Actual.
Before: 15 participants (planned). After: 16 participants (actual).
Before: Recruiting. After: Active not recruiting.